These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23190065)

  • 1. Modern antiplatelet agents in coronary artery disease.
    Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.
    Antonino MJ; Jeong YH; Tantry US; Bliden KP; Gurbel PA
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1011-22. PubMed ID: 23030291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
    Bernlochner I; Byrne RA; Kastrati A; Sibbing D
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor for the treatment of arterial thrombosis.
    Gurbel PA; Kereiakes DJ; Tantry US
    Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Behan MW; Chew DP; Aylward PE
    Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors.
    Chandrasekar S; Loomba R; Shah P; Arora R
    Am J Ther; 2013; 20(4):337-43. PubMed ID: 21519219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
    Höchtl T; Tentzeris I; Schrör K; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):2-10. PubMed ID: 21831128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
    Badr Eslam R; Lang IM; Kaider A; Panzer S
    Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
    Trenk D; Kristensen SD; Hochholzer W; Neumann FJ
    Thromb Haemost; 2013 May; 109(5):834-45. PubMed ID: 23238773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Tomasello SD; Tello-Montoliu A; Angiolillo DJ
    Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.
    Price MJ; Barker CM
    Biomark Med; 2011 Feb; 5(1):43-51. PubMed ID: 21319964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel: the data, the experience, and the controversies.
    Sadanandan S; Singh IM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors.
    Ogawa H; Hokimoto S; Kaikita K; Yamamoto K; Chitose T; Ono T; Tsujita K
    J Cardiol; 2011 Jul; 58(1):6-17. PubMed ID: 21530174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
    Menown IB
    Biomark Med; 2011 Feb; 5(1):1-3. PubMed ID: 21319960
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.